Alternative tools allowed the US Food and Drug Administration to avoid a substantial number of prior approval inspections during the coronavirus pandemic, potentially helping cement their use in the post-COVID-19 world.
Sau Lee, deputy director of science in the FDA Center for Drug Evaluation and Research’s Office of Pharmaceutical Quality, said...






